Clinical and Ultrasound Manifestations of Immune Checkpoint Inhibitor-Associated Enterocolitis:Report of One Case

Xiaoyan ZHANG; Jing QIN; Xiaoqing LI; Guannan ZHANG; Wenbo LI

doi:10.3881/j.issn.1000-503X.16799

PDF(1362 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (5) : 771-775. DOI: 10.3881/j.issn.1000-503X.16799

Clinical Application of Gastrointestinal Ultrasound

Clinical and Ultrasound Manifestations of Immune Checkpoint Inhibitor-Associated Enterocolitis:Report of One Case

Author information +

History +

Abstract

Immune checkpoint inhibitor-associated enterocolitis is an immune-related adverse reaction during tumor treatment with immune checkpoint inhibitors.In this article,we present the clinical data and ultrasound manifestations of a patient with immune checkpoint inhibitor-associated enterocolitis,aiming to share diagnostic and therapeutic insights.

Key words

immune checkpoint inhibitors / enterocolitis / ultrasound

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Xiaoyan ZHANG , Jing QIN , Xiaoqing LI , et al . Clinical and Ultrasound Manifestations of Immune Checkpoint Inhibitor-Associated Enterocolitis:Report of One Case[J]. Acta Academiae Medicinae Sinicae. 2025, 47(5): 771-775 https://doi.org/10.3881/j.issn.1000-503X.16799

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Rajha E, Chaftari P, Kamal M, et al. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy[J]. Gastroenterol Rep(Oxf), 2020, 8(1):25-30.DOI:10.1093/gastro/goz065. Cited in this article [2]

[2]	Collins M, Soularue E, Marthey L, et al. Management of patients with immune checkpoint inhibitor-induced enterocolitis:a systematic review[J]. Clin Gastroenterol Hepatol, 2020, 18(6):1393-1403.e1391.DOI:10.1016/j.cgh.2020.01.033. Cited in this article [3]

[3]	Wang S, Wang H. Treatment of immune checkpoint inhibitor-related colitis:a narrative review[J]. Transl Cancer Res, 2024, 13(12):7002-7014.DOI:0.21037/tcr-24-2150. Cited in this article [1]

[4]	Haryal A, Townsend MJ, Baskaran V, et al. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis,which impacts the clinical course[J]. Cancer, 2023, 129(3):367-375.DOI:10.1002/cncr.34543. Cited in this article [1]

[5]	Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors:a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12):1721-1728.DOI:10.1001/jamaoncol.2018.3923. Cited in this article [1]

[6]	谭蓓, 王汉萍, 李玥, 等. 免疫检查点抑制剂相关结肠炎八例临床特征分析[J]. 中华消化杂志, 2021, 41(5):330-335.DOI:10.3760/cma.j.cn311367-20201014-00602. Cited in this article [2]

[7]	Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer(SITC)clinical practice guideline on immune checkpoint inhibitor-related adverse events[J]. J Immunother Cancer, 2021, 9(6):e002435.DOI:10.1136/jitc-2021-002435. Cited in this article [1]

[8]	Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies[J]. Ann Oncol, 2017, 28(11):2860-2865.DOI:10.1093/annonc/mdx403. Cited in this article [1]

[9]	Alessandrino F, Sahu S, Nishino M, et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor[J]. Abdom Radiol(NY), 2019, 44(5):1917-1927.DOI:10.1007/1s00261-019-01935-2. Cited in this article [2]

[10]	Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis:CT findings[J]. AJR Am J Roentgenol, 2013, 200(5):W468-W474.DOI:10.2214/AJR.12.9751. Cited in this article [2]

[11]	Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab[J]. Cancer Immunol Res, 2015, 3(10):1185-1192.DOI:10.1158/2326-6066.CIR-15-0102. Cited in this article [1]

[12]

Reijntjes

, de Voogd

FAE

, Bemelman

, et al. Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls-a prospective cohort study[J]. Aliment Pharmacol Ther, 2023, 57(1):127-135.DOI:10.1111/apt.17267.

Cited in this article [1]

[13]	Shirwaikar Thomas A, Hanauer S, Wang Y. Immune checkpoint inhibitor enterocolitis vs. idiopathic inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2023, 21(4):878-890.DOI:10.1016/j.cgh.2022.10.004. Cited in this article [1]

[14]	Gupta T, Antanaviciute A, Hyun-Jung Lee C, et al. Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis[J]. Cancer Cell, 2024, 42(5):797-814.e715.DOI:10.1016/j.ccell.2024.04.010. Cited in this article [1]

[15]

Hone

Lopez S

, Kats-Ugurlu

, Renken

, et al. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8⁺ T cells and an infiltration pattern that resembles ulcerative colitis[J]. Virchows Arch, 2021, 479(6):1119-1129.DOI:10.1007/s00428-021-03170-x.

Cited in this article [1]

[16]	Voelker R. What is ulcerative colitis[J]. JAMA, 2024, 331(8):716.DOI:10.1001/jama.2023.23814. Cited in this article [1]

[17]	Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis[J]. Lancet, 2012, 380(9853):1606-1619.DOI:10.1016/S0140-6736(12)60150-0. Cited in this article [1]

[18]	Maconi G, Nylund K, Ripolles T, et al. EFSUMB recommendations and clinical guidelines for intestinal ultrasound(GIUS)in inflammatory bowel diseases[J]. Ultraschall Med, 2018, 39(3):304-317.DOI:10.1055/s-0043-125329. Cited in this article [1]